当前位置:首页 - 行情中心 - 恒瑞医药(600276) - 财务分析 - 现金流量表

恒瑞医药

(600276)

  

流通市值:2751.26亿  总市值:2862.62亿
流通股本:63.79亿   总股本:66.37亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金13,442,616,615.046,671,724,436.3633,605,876,222.7426,173,262,016.04
  收到其他与经营活动有关的现金914,541,634.64252,626,908.491,228,283,666.84799,560,767.34
  经营活动现金流入小计14,357,158,249.686,924,351,344.8534,834,159,889.5826,972,822,783.38
  购买商品、接受劳务支付的现金809,768,240.91379,189,175.22,099,963,151.921,167,102,744.63
  支付给职工以及为职工支付的现金4,028,999,278.742,166,754,419.697,004,960,838.625,462,509,586.42
  支付的各项税费1,549,705,077.79698,501,493.042,787,135,744.231,839,015,825.49
  支付其他与经营活动有关的现金5,981,681,779.92,893,460,356.2111,706,722,024.189,393,764,336.57
  经营活动现金流出小计12,370,154,377.346,137,905,444.1423,598,781,758.9517,862,392,493.11
  经营活动产生的现金流量净额1,987,003,872.34786,445,900.7111,235,378,130.639,110,430,290.27
二、投资活动产生的现金流量:
  收回投资收到的现金--151,000,000151,000,000
  取得投资收益收到的现金15,678,236.94518,588.5151,492,129.4430,047,582.88
  处置固定资产、无形资产和其他长期资产收回的现金净额52,528,697.1510,854,350.5518,911,785.277,147,978.59
  投资活动现金流入小计68,206,934.0911,372,939.06221,403,914.71188,195,561.47
  购建固定资产、无形资产和其他长期资产支付的现金1,577,505,322.86704,818,964.872,961,906,284.581,714,462,484.69
  投资支付的现金315,300,00030,300,000--
  投资活动现金流出小计1,892,805,322.86735,118,964.872,961,906,284.581,714,462,484.69
  投资活动产生的现金流量净额-1,824,598,388.77-723,746,025.81-2,740,502,369.87-1,526,266,923.22
三、筹资活动产生的现金流量:
  吸收投资收到的现金--10,351,937,892.2810,351,937,892.28
  取得借款收到的现金1,491,095,462.51299,534,222.251,495,572,622.12428,335,302.78
  收到其他与筹资活动有关的现金--418,168,545-
  筹资活动现金流入小计1,491,095,462.51299,534,222.2512,265,679,059.410,780,273,195.06
  偿还债务支付的现金1,493,174,955300,000,0001,500,000,000-
  分配股利、利润或偿付利息支付的现金1,328,140,177.29-1,284,255,700.451,274,130,192.8
  支付其他与筹资活动有关的现金259,566,906.03185,251,178.591,699,715,987.251,415,122,611.08
  筹资活动现金流出小计3,080,882,038.32485,251,178.594,483,971,687.72,689,252,803.88
  筹资活动产生的现金流量净额-1,589,786,575.81-185,716,956.347,781,707,371.78,091,020,391.18
四、汇率变动对现金及现金等价物的影响-696,646,671.36-349,701,516.56-360,132,552.71-146,577,748.58
五、现金及现金等价物净增加额-2,124,027,763.6-472,718,59815,916,450,579.7515,528,606,009.65
  加:期初现金及现金等价物余额40,155,552,697.4140,155,552,697.4124,239,102,117.6624,239,102,117.66
  期末现金及现金等价物余额38,031,524,933.8139,682,834,099.4140,155,552,697.4139,767,708,127.31
补充资料:
  净利润4,465,282,419.88-7,717,002,245.78-
  资产减值准备18,334,072.43-86,914,039.97-
  固定资产和投资性房地产折旧396,210,578.75-689,203,837.11-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧396,210,578.75-689,203,837.11-
  无形资产摊销91,168,178.35-114,581,839.37-
  长期待摊费用摊销32,655,550.32-97,702,799.02-
  处置固定资产、无形资产和其他长期资产的损失-40,624,532.98--4,053,134.77-
  固定资产报废损失5,500,257.83-3,289,843.5-
  公允价值变动损失-843,222,978.34--173,573,838.21-
  财务费用668,524,563.32-374,481,650.12-
  投资损失56,444,685.47-57,480,679.6-
  递延所得税151,624,594.49--403,931,406.24-
  其中:递延所得税资产减少-6,812,004.91--403,782,268.44-
    递延所得税负债增加158,436,599.4--149,137.8-
  存货的减少-133,892,624.92--479,237,472.88-
  经营性应收项目的减少-766,018,031.54--1,097,175,061.93-
  经营性应付项目的增加-2,309,045,675.46-4,134,810,119.38-
  其他180,307,909.1-53,018,404.41-
  现金的期末余额38,031,524,933.81-40,155,552,697.41-
  减:现金的期初余额40,155,552,697.41-24,239,102,117.66-
  现金及现金等价物的净增加额-2,124,027,763.6-15,916,450,579.75-
公告日期2026-08-202026-04-232026-03-262025-10-28
审计意见(境内)标准无保留意见
TOP↑